// App-Quantinova.ai

71 : Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically.

Researchers

Presenter

  • Yongwoo David Seo

Principal Investigators

  • Kevin Morse

  • Jeremy Patino

  • Sean Mackay

  • Edward Y. Kim

  • Ernest U. Conrad

  • Ryan Blair O'Malley

  • Lee D. Cranmer

  • Hailing Lu

  • Frank J. Hsu

  • Yuexin Xu

  • Elizabeth Trice Loggers

  • Taylor Hain

  • Venu Gopal Pillarisetty

  • Gabrielle Kane

  • Stanley Riddell

  • Jan H. ter Meulen

  • Robin Lewis Jones

  • Seth Pollack

Medical Centers

  • University of Washington, Seattle, WA

  • IsoPlexis, Branford, CT

  • IsoPlexis, Branford, CT

  • Seattle Children's, Seattle, WA

  • Immune Design, Seattle, WA

  • Immune Design, South San Francisco, CA

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Seattle Cancer Care Alliance, Seattle, WA

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 4

  • Toll like receptor 4

  • T-cell receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02180698

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved